Supplementary Figure Legends

Supplementary Figure S1. The full-length gel of Figure 1A.

(A) The original, uncropped Western blot image for BCL2 shown in Figure 1A.
(B) The original, uncropped Western blot image for β-actin in Figure 1A.

Supplementary Figure S2. The densitometry ratios of Figure 1A.

(A) The densitometry ratio of BCL2 relative to β-actin of Figure 1A was quantified by ImageJ.

Supplementary Figure S3. The inhibitory effect of venetoclax on the viable cell numbers of EBV-infected T- or NK-cell lines.

IC50 was calculated for each cell line at two time points (24 and 48 hours). The inhibition of cell numbers in the control (0 μM) was defined as 0%, and the concentration at which venetoclax inhibited cell numbers by 50% was calculated. The vertical axis represents the percentage of cell count inhibition (InH (%)). The half-inhibitory concentration (IC50) was calculated using GraphPad Prism and Excel.

(A, B) IC50 value of vanetoclax in SNT8 in Figure 1B.

(C, D) IC50 value of vanetoclax in SNT15 in Figure 1D.

(E, F) IC50 value of vanetoclax in SNT16 in Figure 1F.

(G, H) IC50 value of vanetoclax in SNK1 in Figure 1C.

(I, J) IC50 value of vanetoclax in SNK6 in Figure 1E.

(K, L) IC50 value of vanetoclax in SNK10 in Figure 1G.

(M, N) IC50 value of vanetoclax in Karpas231 in Figure 1H.

(O, P) IC50 value of vanetoclax in SU-DHL10 in Figure 1I.

Supplementary Figure S4. The full-length gel for Figure 2B.

(A) The original, uncropped western blot image for PARP in Figure 2B.
(B) The original, uncropped western blot image for Caspase-3 in Figure 2B.
(C) The original, uncropped western blot image for β-actin in Figure 2B.

Supplementary Figure S5. The full-length gel for Figure 3A.

(A) The original, uncropped western blot image for BCL2 in Figure 3A.
(B) The original, uncropped western blot image for BAX in Figure 3A.
(C) The original, uncropped western blot image for BAK in Figure 3A.
(D) The original, uncropped western blot image for β-actin in Figure 3A.

Supplementary Figure S6. The inhibitory effect of venetoclax on the viable cell numbers of sCAEBV patients' PBMCs.

IC50 was calculated for each patient at two time points (24 and 48 hours). The inhibition of cell numbers in the control (0 μM) was defined as 0%, and the concentration at which venetoclax inhibited cell numbers by 50% was calculated. The vertical axis represents the percentage of cell count inhibition (InH (%)). The half-inhibitory concentration (IC50) was calculated using GraphPad Prism and Excel.

(A, B) IC50 value of vanetoclax in Patient 1 in Figure 4A.

(C, D) IC50 value of vanetoclax in Patient 2 in Figure 4B.

(E, F) IC50 value of vanetoclax in Patient 3 in Figure 4C.

(G, H) IC50 value of vanetoclax in Patient 4 in Figure 4D.

(I, J) IC50 value of vanetoclax in Patient 5 in Figure 4E.

Supplementary Figure S7. The effect of venetoclax to the expression of phospho-STAT3.

(A, B) The expression of phospho-STAT3 (Tyr705), phospho-STAT3 (Ser727) and STAT3 before and after the stimulation with 1 μM venetoclax was detected by western blotting analysis and quantified in the densitometry ratios relative to β-actin in (A) SNT8, SNT15, SNT16 and (B) SNK1, SNK6, SNK10.

Figure S1 A


Jurkat
KHYG1
SNT8
SNT15
SNT16
SNK1
SNK6
SNK10
Karpas231
SU-DHL10
BCL2

B


Jurkat
KHYG1
SNT8
SNT15
SNT16
SNK1
SNK6
SNK10
Karpas231
SU-DHL10
β-actin

Figure S2

A


BCL2/β-actin ratio
1.4
1.2
1
0.8
0.6
0.4
0.2
0
SNT8
SNT15
SNT16
SNK1
SNK6
SNK10
Karpas231
SU-DHL10

Figure S3


A
SNT8 (24 h)
IC50 = 3.099 μM
InH (%)
Ventcoclax (μM)
B
SNT8 (48 h)
IC50 = 1.949 μM
InH (%)
Ventcoclax (μM)
C
SNT15 (24 h)
IC50 = 0.347 μM
InH (%)
Ventcoclax (μM)
D
SNT15 (48 h)
IC50 < 0.200 μM
InH (%)
Ventcoclax (μM)
E
SNT16 (24 h)
IC50 = 1.408 μM
InH (%)
Ventcoclax (μM)
F
SNT16 (48 h)
IC50 = 1.122 μM
InH (%)
Ventcoclax (μM)

Figure S3


G
SNK1 (24 h)
IC50 = 3.599 μM
InH (%)
Ventcoclax (μM)
H
SNK1 (48 h)
IC50 = 3.417 μM
InH (%)
Ventcoclax (μM)
I
SNK6 (24 h)
IC50 = 2.525 μM
InH (%)
Ventcoclax (μM)
J
SNK6 (48 h)
IC50 = 2.153 μM
InH (%)
Ventcoclax (μM)
K
SNK10 (24 h)
IC50 = 0.509 μM
InH (%)
Ventcoclax (μM)
L
SNK10 (48 h)
IC50 = 0.388 μM
InH (%)
Ventcoclax (μM)

Figure S3


M
Karpas231 (24 h)
IC50 < 0.200 µM
InH (%)
Ventcoclax (µM)
N
Karpas231 (48 h)
IC50 < 0.200 µM
InH (%)
Ventcoclax (µM)
O
SU-DHL10 (24 h)
IC50 > 4.000 µM
InH (%)
Ventcoclax (µM)
P
SU-DHL10 (48 h)
IC50 > 4.000 µM
InH (%)
Ventcoclax (µM)

Figure S4


A
SNT8 SNT15 SNT16 SNK1 SNK6 SNK10
Venetoclax: - + - + - + - + - + - +
PARP
cleaved PARP
B
SNT8 SNT15 SNT16 SNK1 SNK6 SNK10
Venetoclax: - + - + - + - + - + - +
Caspase-3
cleaved Caspase-3
C
SNT8 SNT15 SNT16 SNK1 SNK6 SNK10
Venetoclax: - + - + - + - + - + - +
β-actin

Figure S5


A
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
SNT16
SNK10
SU-DHL10
BCL2
B
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
SNT16
SNK10
SU-DHL10
BAX
C
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
SNT16
SNK10
SU-DHL10
BAK
D
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
SNT16
SNK10
SU-DHL10
β-actin

Figure S6


A
Patient 1 (24 h)
IC50 > 4.000 µM
B
Patient 1 (48 h)
IC50 > 4.000 µM
C
Patient 2 (24 h)
IC50 > 4.000 µM
D
Patient 2 (48 h)
IC50 = 2.787 µM
E
Patient 3 (24 h)
IC50 > 4.000 µM
F
Patient 3 (48 h)
IC50 > 4.000 µM
G
Patient 4 (24 h)
IC50 > 4.000 µM
H
Patient 4 (48 h)
IC50 > 4.000 µM
I
Patient 5 (24 h)
IC50 > 4.000 µM
J
Patient 5 (48 h)
IC50 > 4.000 µM
InH (%)
Ventcoclax (µM)

Figure S7


A
SNT8
SNT15
SNT16
Venetoclax: - + - + - +
pSTAT3 (Tyr705)
pSTAT3 (Ser727)
STAT3
B-actin
p-STAT3 (Tyr)/STAT3 ratio
1.4
1.2
1
0.8
0.6
0.4
0.2
0
- + - + - +
SNT8 SNT15 SNT16
p-STAT3 (Ser)/STAT3 ratio
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
- + - + - +
SNT8 SNT15 SNT16
B
SNK1
SNK6
SNK10
Venetoclax: - + - + - +
pSTAT3 (Tyr705)
pSTAT3 (Ser727)
STAT3
B-actin
p-STAT3 (Tyr)/STAT3 ratio
3.5
3
2.5
2
1.5
1
0.5
0
- + - + - +
SNK1 SNK6 SNK10
p-STAT3 (Ser)/STAT3 ratio
2.5
2
1.5
1
0.5
0
- + - + - +
SNK1 SNK6 SNK10